Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma.


Journal

Endocrine-related cancer
ISSN: 1479-6821
Titre abrégé: Endocr Relat Cancer
Pays: England
ID NLM: 9436481

Informations de publication

Date de publication:
01 Apr 2024
Historique:
received: 18 12 2023
accepted: 16 02 2024
medline: 18 3 2024
pubmed: 16 2 2024
entrez: 16 2 2024
Statut: epublish

Résumé

We developed a novel contemporary population-based model for predicting cancer-specific survival (CSS) in adrenocortical carcinoma (ACC) patients and compared it with the established 8th edition of the American Joint Committee on Cancer staging system (AJCC). Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified 1056 ACC patients. Univariable Cox regression model addressed CSS. Harrell's concordance index (C-index) quantified accuracy after 2000 bootstrap resamples for internal validation. The multivariable Cox regression model included the most informative, statistically significant predictors. Calibration and decision curve analyses (DCAs) tested the multivariable model as well as AJCC in head-to-head comparisons. Age at diagnosis (>60 vs ≤60 years), surgery, T, N, and M stages were included in the multivariable model. Multivariable model C-index for 3-year CSS prediction was 0.795 vs 0.757 for AJCC. Multivariable model outperformed AJCC in DCAs for the majority of possible CSS-predicted values. Both models exhibited similar calibration properties. Finally, the range of the multivariable model CSS predicted probabilities raged 0.02-75.3% versus only four single AJCC values, specifically 73.2% for stage I, 69.7% for stage II, 46.6% for stage III, and 15.5% for stage IV. The greatest benefit of the multivariable model-generated CSS probabilities applied to AJCC stage I and II patients. The multivariable model was more accurate than AJCC staging when CSS predictions represented the endpoint. Additionally, the multivariable model outperformed AJCC in DCAs. Finally, the AJCC appeared to lag behind the multivariable model when discrimination addressed AJCC stage I and II patients.

Identifiants

pubmed: 38363202
doi: 10.1530/ERC-23-0353
pii: ERC-23-0353
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Letizia Maria Ippolita Jannello (LMI)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Department of Urology IEO European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy.
Università degli Studi di Milano, Milan, Italy.

Simone Morra (S)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.

Lukas Scheipner (L)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Department of Urology, Medical University of Graz, Graz, Austria.

Andrea Baudo (A)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Università degli Studi di Milano, Milan, Italy.
Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.

Carolin Siech (C)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.

Mario de Angelis (M)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Nawar Touma (N)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Zhe Tian (Z)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Jordan A Goyal (JA)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Stefano Luzzago (S)

Department of Urology IEO European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy.
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Francesco A Mistretta (FA)

Department of Urology IEO European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy.
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Mattia Luca Piccinelli (ML)

Department of Urology IEO European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy.
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Fred Saad (F)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Felix K H Chun (FKH)

Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.

Alberto Briganti (A)

Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Sascha Ahyai (S)

Department of Urology, Medical University of Graz, Graz, Austria.

Luca Carmignani (L)

Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.
Department of Urology, IRCCS Ospedale Galeazzi - Sant'Ambrogio, Milan, Italy.

Nicola Longo (N)

Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.

Ottavio de Cobelli (O)

Department of Urology IEO European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy.
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Gennaro Musi (G)

Department of Urology IEO European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy.
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Pierre I Karakiewicz (PI)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH